KRAS and cancer: Previous reports (Sanchez-Cespedes et al, 2002; Carretero et al, 2004) and Cancer Genome Project by Sanger Institute (Bamford et al, 2004) have extensively characterised LKB1 mutations in NSCLC cell lines with KRAS and BRAF mutations, but LKB1 status of EGFR mutant NSCLC cell lines has not been extensively analysed.